(Q36428382)

English

Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Crohn's disease

0 references

quality of life

1 reference

based on heuristic

inferred from title

1

object named as

Paul Rutgeerts

0 references

Richard N. Fedorak

object named as

Richard N Fedorak

6

0 references

Brian G. Feagan

3

object named as

Brian Feagan

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Stefan Schreiber

2

object named as

Stefan Schreiber

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Dorothy L Keininger

4

object named as

Dorothy L Keininger

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

author name string

Liz O'Neil

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

CDP870 Crohn's Disease Study Group

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

publication date

11 December 2007

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

International Journal of Colorectal Disease

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

23

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

289-296

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

30 September 2017

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

30 September 2017

Natalizumab for active Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

30 September 2017

The quality of life in patients with Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

30 September 2017

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

30 September 2017

A critical assessment of new therapies in inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

30 September 2017

Review article: the limitations of corticosteroid therapy in Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

30 September 2017

Steroid-dependent Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

30 September 2017

Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

30 September 2017

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

30 September 2017

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

30 September 2017

Health status in inflammatory bowel disease. Biological and behavioral considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

30 September 2017

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

30 September 2017

Tumour necrosis factor and Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

28 June 2018

The quality of life in Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

28 June 2018

Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

28 June 2018

Long-term prognosis in Crohn's disease: factors that affect quality of life.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

21 September 2018

Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

21 September 2018

The effects of infliximab maintenance therapy on health-related quality of life.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

21 September 2018

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

21 September 2018

Infliximab improves quality of life in patients with Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

21 September 2018

Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

21 September 2018

Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

21 September 2018

Influence of inflammatory bowel disease on different dimensions of quality of life.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

21 September 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2225995

4 December 2018

A new measure of health status for clinical trials in inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18071721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Responsiveness and validity in health status measurement: a clarification

1 reference

https://pubmed.ncbi.nlm.nih.gov/18071721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The rating form of IBD patient concerns: a new measure of health status

1 reference

https://pubmed.ncbi.nlm.nih.gov/18071721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18071721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18071721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00384-007-0395-7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36428382&oldid=2198879295"